People Briefs
This article was originally published in The Gray Sheet
Executive Summary
Epigenomics, RainDance, and Brightree name new leadership, and more personnel news from around the industry.
You may also be interested in...
Life After NASH For CymaBay: An Interview With CEO Sujal Shah
With up to $100m from Abingworth and a recent $75m FOPO, CymaBay has runway to await pivotal data in primary biliary cholangitis in 2023 for seladelpar, after the candidate failed in NASH. It sees a significant market opportunity in the second-line setting cornered by Intercept.
FDA, Industry To Miss MDUFA V Congressional Deadline; Insiders At Odds Over Future Of Deal
The US agency and the medtech industry still have significant disagreements, which means they will miss a 15 January deadline to send the MDUFA V user-fee deal to Congress. Insiders disagree, however, on how severe those disagreements are and when a deal can be reached.
Device Week, 14 January 2022 – Battle For The Right To Repair Devices Heats Up In US States
On this week’s podcast: From Hawaii to Missouri to Florida, the medtech industry and third-party servicers are duking it out in state legislatures over who has the right to repair and service medical devices.